Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
- Conditions
- Adult Acute Lymphocytic Leukemia
- Interventions
- Drug: CyclophosphamideDrug: DexamethasoneDrug: VincristineDrug: DaunorubicinDrug: AsparaginaseDrug: MethotrexateDrug: CytarabineDrug: MercaptopurineDrug: G-CSFDrug: VindesineDrug: EtoposideDrug: PrednisoloneDrug: AdriamycinDrug: ThioguanineDrug: TeniposideProcedure: CNS irradiationProcedure: Mediastinal IrradiationProcedure: Stem cell transplantation (SCT)Drug: IdarubicinDrug: FludarabineDrug: Cladribine
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 1883
- Registration Number
- NCT00198991
- Locations
- 🇩🇪
University of Frankfurt, Medical Dept. II, Frankfurt, Germany
German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Adult Acute Lymphocytic Leukemia
- Interventions
- Drug: CyclophosphamideDrug: Dexamethasone / PrednisoloneDrug: CytarabineDrug: IdarubicinDrug: Granulocyte-Colony-Stimulating FactorDrug: MercaptopurineDrug: MethotrexateDrug: RituximabDrug: HDARACDrug: VincristineDrug: DepocyteDrug: Asparaginase
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 377
- Registration Number
- NCT00198978
- Locations
- 🇩🇪
University of Frankfurt, Medical Dept. II, Frankfurt, Germany
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)
- Conditions
- Adult Acute Lymphocytic Leukemia
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 720
- Registration Number
- NCT00199069
- Locations
- 🇩🇪
University Hospital, Medical Dept. II, Frankfurt, Germany
Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults
- Conditions
- Burkitt's LymphomaBurkitt's LeukemiaMediastinal NeoplasmsLymphoblastic LymphomaLarge Cell Anaplastic Lymphoma
- Interventions
- Drug: AdriamycinDrug: CyclophosphamideDrug: CytarabineDrug: Dexamethasone/PrednisoloneDrug: VP16Drug: IfosfamideDrug: MethotrexateDrug: G-CSFDrug: RituximabDrug: Vincristine/VindesineProcedure: Irradiation (in specific conditions)
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2022-08-19
- Lead Sponsor
- Nicola Goekbuget
- Target Recruit Count
- 650
- Registration Number
- NCT00199082
- Locations
- 🇩🇪
University Hospital, Medical Dept. II, Frankfurt, Germany
Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab
- Conditions
- Adult Acute Lymphocytic Leukemia
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2010-08-23
- Lead Sponsor
- Johann Wolfgang Goethe University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT00199004
- Locations
- 🇩🇪
University Hospital of Frankfurt, Medical Dept. II, Frankfurt, Germany
Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)
- Conditions
- Philadelphia Positive Acute Lymphoblastic LeukemiaLymphoid Blastic Phase of Chronic Myeloid Leukemia
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2007-10-19
- Lead Sponsor
- Johann Wolfgang Goethe University Hospital
- Registration Number
- NCT00199186
- Locations
- 🇩🇪
Medizinische Klinik II, Johann Wolfgang Goethe Universität, Frankfurt/Main, Germany
Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia
- Conditions
- Adult Acute Lymphocytic Leukemia
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 40
- Registration Number
- NCT00199095
- Locations
- 🇩🇪
University Hospital, Medical Dept. II, Frankfurt, Germany
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)
- Conditions
- Adult Acute Lymphocytic Leukemia
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 225
- Registration Number
- NCT00199056
- Locations
- 🇩🇪
University Hospital, Medical Dept. II, Frankfurt, Germany
A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN)
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- German Breast Group
- Target Recruit Count
- 3000
- Registration Number
- NCT00196872
- Locations
- 🇩🇪
Städtische Kliniken Frankfurt a.M.-Höchst, Frankfurt, Hessia, Germany
Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G-CSF for 12 Wks; Wkly Taxol x 12
- Conditions
- Breast Neoplasm
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-09-13
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 80
- Registration Number
- NCT00194753
- Locations
- 🇺🇸
University of Washington/Seattle Cancer Care Alliance, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.